Life Sciences · Nasdaq: ILMN
Illumina earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends January · next results expected around 4 Feb 2027
Latest: Q3 FY2026
Illumina is pairing strong NovaSeq X placements and clinical sequencing demand with a push into AI-ready biology data via its Billion Cell Atlas, now over halfway complete.
Clinical sequencing demand and NovaSeq X placements drove the quarter, with over 80 instruments placed. Clinical consumables grew 14 % in the rest of the world, while research and applied consumables kept shrinking. Several of the largest clinical customers placed multi-unit capacity orders. Illumina also launched the BioInsight analysis platform with a new splicing AI model. GSK joined the Billion Cell Atlas Consortium, and interest in leases is rising among research and mid-size clinical labs.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 FY24 | $1.1B * |
| Q1 FY25 | $1.0B |
| Q2 FY25 | $1.1B |
| Q3 FY25 | $1.1B |
| Q4 FY25 | $1.2B * |
| Q1 FY26 | $1.1B |
| Q2 FY26 | $1.2B |
| Q3 FY26 | $1.1B |
Data
| Q1 FY25 | $0.82 |
| Q2 FY25 | $1.49 |
| Q3 FY25 | $0.98 |
| Q1 FY26 | $0.87 |
| Q2 FY26 | $1.35 |
| Q3 FY26 | $1.43 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 FY24 | 15.9% |
| Q1 FY25 | 15.8% |
| Q2 FY25 | 20.2% |
| Q3 FY25 | 20.9% |
| Q4 FY25 | 17.3% |
| Q1 FY26 | 19.2% |
| Q2 FY26 | 21.1% |
| Q3 FY26 | 27.0% |
Data
| Q4 FY24 | $335.0M |
| Q1 FY25 | $208.0M |
| Q2 FY25 | $204.0M |
| Q3 FY25 | $253.0M |
| Q4 FY25 | $266.0M |
| Q1 FY26 | $251.0M |
| Q2 FY26 | $161.0M |
| Q3 FY26 | $379.0M |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1Bd | $1.0B | $1.1B | $1.1B | $1.2Bd | $1.1B | $1.2B | $1.1B |
| Gross margin | 65.9% | 65.6% | 65.6% | 67.6% | 65.5% | 66.1% | 66.4% | 73.5% |
| Operating income | $175.0Md | $164.0M | $214.0M | $227.0M | $201.0Md | $209.0M | $245.0M | $305.0M |
| Operating margin | 15.9% | 15.8% | 20.2% | 20.9% | 17.3% | 19.2% | 21.1% | 27.0% |
| Net income | $186.0M | $131.0M | $235.0M | $150.0M | $334.0M | $134.0M | $207.0M | $220.0M |
| Diluted EPS | — | $0.82 | $1.49 | $0.98 | — | $0.87 | $1.35 | $1.43 |
| Operating cash flow | $364.0Md | $240.0M | $234.0Md | $284.0Md | $321.0Md | $289.0M | $201.0Md | $419.0Md |
| Capital expenditure | $29.0Md | $32.0M | $30.0Md | $31.0Md | $55.0Md | $38.0M | $40.0Md | $40.0Md |
| Free cash flow | $335.0M | $208.0M | $204.0M | $253.0M | $266.0M | $251.0M | $161.0M | $379.0M |
| R&D expense | $256.0Md | $252.0M | $247.0M | $229.0M | $239.0Md | $240.0M | $252.0M | $244.0M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 30 Oct 202610-Q for the period ended 27 Sep 2026SEC ↗
- 31 Jul 202610-Q for the period ended 28 Jun 2026SEC ↗
- 4 May 202610-Q for the period ended 29 Mar 2026SEC ↗
- 12 Feb 202610-K for the period ended 28 Dec 2025SEC ↗
- 31 Oct 202510-Q for the period ended 28 Sep 2025SEC ↗
- 1 Aug 202510-Q for the period ended 29 Jun 2025SEC ↗
- 9 May 202510-Q for the period ended 30 Mar 2025SEC ↗
- 12 Feb 202510-K for the period ended 29 Dec 2024SEC ↗